Progression-free survival

Artikelen filtered by tag "progression-free survival"

The following articles contain the tag progression-free survival:


Erlotinib (Tarceva®) was the first EGFR tyrokinase inhibitor to be authorized for the treatment of non-small-cell lung carcinoma (NSCLC). It enabled outpatient treatment, and has a more favourable adverse effects profile than the existing chemoth ...

In short Read article